Département d'Immunologie, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.
Clin Immunol. 2011 Mar;138(3):239-46. doi: 10.1016/j.clim.2010.11.012. Epub 2010 Dec 28.
NMO-IgG is a specific biomarker of neuromyelitis optica (NMO) that targets the aquaporin-4 (AQP4) water channel protein. The current gold standard for NMO-IgG identification is indirect immunofluorescence (IIF). Our aim in this study was to develop a new quantitative cell-based assay (CBA) and to propose a rational strategy for anti-AQP4 Ab identification and quantification. We observed an excellent correlation between the CBA and IIF for NMO-IgG/anti-AQP4 detection. The CBA appeared more sensitive than IIF but on the other hand, IIF allows the simultaneous detection of various auto-Abs, underlining the complementarity between both methods. In conclusion, we propose to use IIF for the screening of patients at diagnosis in order to identify auto-Abs targeting the central nervous system. A highly sensitive, AQP4 specific and quantitative assay such as our CBA could be used thereafter to specifically identify the target of the Ab and to monitor its serum concentration under treatment.
NMO-IgG 是视神经脊髓炎（NMO）的一种特异性生物标志物，针对水通道蛋白 4（AQP4）。目前，NMO-IgG 的鉴定金标准是间接免疫荧光法（IIF）。本研究旨在开发一种新的基于细胞的定量测定法（CBA），并提出一种用于抗 AQP4 Ab 鉴定和定量的合理策略。我们观察到 CBA 与 IIF 在检测 NMO-IgG/抗 AQP4 方面具有极好的相关性。CBA 似乎比 IIF 更敏感，但另一方面，IIF 允许同时检测多种自身抗体，强调了这两种方法的互补性。总之，我们建议在诊断时使用 IIF 对患者进行筛选，以识别针对中枢神经系统的自身抗体。此后，可以使用高度敏感、针对 AQP4 且具有定量测定能力的测定法，如我们的 CBA，特异性地鉴定 Ab 的靶标，并在治疗过程中监测其血清浓度。
